ORYZON GENOMICS SA
Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders. Oryzon is able to identify and validate biomarkers and therapeutic targets through its epigenetic platform and turn them into advanced and personalized therapies. Oryzon Genomics has a growing portfolio, with two compounds in Phase II clinical trials: iadademstat (aka ORY-1001), a potent and selective LSD1 inhibitor for oncology, and vafidemstat (aka ORY-2001), a CNS optimized LSD1 inhibitor for the treatment of neurological diseases. The portfolio includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases.
ORYZON GENOMICS SA
Social Links:
Industry:
Biopharma Biotechnology Genetics Health Care Medical Therapeutics
Founded:
2000-06-02
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.oryzon.com
Total Employee:
11+
Status:
Active
Contact:
34 93 515 13 13
Email Addresses:
[email protected]
Total Funding:
162.38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Domain Not Resolving
Similar Organizations
CureVac
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.
Elasmogen
Elasmogen is a precision biologics drug discovery company that develops soloMERs.
Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
immatics biotechnologies
immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Medicinal Genomics
Medicinal Genomics is pioneering the genomics of medical cannabis and hemp.
Medreich
Medreich is a fully integrated pharmaceutical company with an established presence across the globe.
NuCana BioMed
NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.
Oxford BioMedica
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research.
Pepgen
PepGen is empowering nucleic acid therapeutics to go the distance.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Regulus Therapeutics
Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.
Theolytics
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
Theranexus
Theranexus is a clinical-stage pharmaceutical company that aims to develop technology to address severe medical needs in brain disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2009-03-20 | Crystax Pharmaceuticals | Crystax Pharmaceuticals acquired by Oryzon Genomics SA | N/A |
Investors List
Nice & Green SA
Nice & Green SA investment in Convertible Note - Oryzon Genomics SA
European Commission
European Commission investment in Grant - Oryzon Genomics SA
Kabuki Syndrome Foundation
Kabuki Syndrome Foundation investment in Grant - Oryzon Genomics SA
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Grant - Oryzon Genomics SA
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Grant - Oryzon Genomics SA
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Grant - Oryzon Genomics SA
ICF Capital
ICF Capital investment in Venture Round - Oryzon Genomics SA
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Grant - Oryzon Genomics SA
Laboratorios Ordesa
Laboratorios Ordesa investment in Series B - Oryzon Genomics SA
Corsabe Capital
Corsabe Capital investment in Series B - Oryzon Genomics SA
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-28 | ORYZON Announces Appointment of Douglas V. Faller, MD, PhD as Global Chief Medical Officer and Continues its Expansion of US Corporate Activities |
Official Site Inspections
http://www.oryzon.com Semrush global rank: 1.67 M Semrush visits lastest month: 14.63 K
- Host name: 172.67.75.163
- IP address: 172.67.75.163
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Oryzon Genomics SA"
Overview - Oryzon
ORYZON is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Our …See details»
Team - Oryzon
Oryzon’s management team is composed of passionate biopharma executives exploring new fields of epigenetic science to transform it into innovative personalized medicines for patients.See details»
Oryzon Genomics SA - Crunchbase Company Profile
Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders. Oryzon is able to identify and validate biomarkers and therapeutic targets through its epigenetic …See details»
Oryzon Genomics Company Description - Stock Analysis
6 days ago Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and …See details»
Oryzon Genomics Company Profile - Office Locations, Competitors …
Oct 29, 2024 Oryzon Genomics is a clinical stage biopharmaceutical company that discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The …See details»
Oryzon Genomics - Org Chart, Teams, Culture & Jobs - The Org
View Oryzon Genomics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Oryzon - Overview, News & Similar companies | ZoomInfo.com
May 5, 2024 ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat MADRID, Spain and CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Oryzon …See details»
Strategy - Oryzon
ORYZON is a clinical stage biopharmaceutical company that leverages epigenetics to discover and develop innovative personalized therapeutics for patients with CNS disorders and cancers.While other companies are exploring …See details»
Oryzon Genomics SA - Funding, Financials, Valuation & Investors
Oryzon Genomics SA is registered under the ticker BME:ORY . Oryzon Genomics SA is funded by 11 investors. The ALS Association and Nice & Green SA are the most recent investors. …See details»
Oryzon Genomics SA - Contacts, Employees, Board Members
Organization. Oryzon Genomics SA . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Number of Board Member and Advisor …See details»
ORYZON Reports Financial Results and Corporate Update for …
Oct 24, 2024 MADRID and CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical …See details»
Oryzon Genomics S.A. (BME: ORY) - Stock Analysis
Dec 20, 2024 Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and …See details»
Collaborations - Oryzon
Oryzon Genomics conducted a preclinical collaboration with the Charcot-Marie-Tooth Research Foundation (CMTRF), a US-based patient-led, non-profit organization focused on delivering …See details»
Oryzon Genomics - Edison Group
Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central …See details»
Oryzon - Overview, News & Competitors | ZoomInfo.com
Oryzon. Business Services · Massachusetts, United States · <25 Employees. Oryzon is the leader in the development of therapeutics in the epigenetic target LSD1: Oryzon has a program in …See details»
Inicio - Oryzon
Dec 2, 2024 ORYZON es una compañía biofarmacéutica de fase clínica que utiliza la epigenética para descubrir y desarrollar terapias personalizadas innovadoras para pacientes …See details»
Home - Orizon | Cyber Security Services
Our Security Operations Center centralizes asset data, providing a coherent picture of the organization’s resources and facilitating efficient security planning. Correlation and Response …See details»
Press releases - Oryzon
Sep 3, 2024 ORYZON receives Notice of allowance for patent on novel technology for measuring LSD1 target engagement. 24 October 2024. ORYZON reports financial results and …See details»